Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company"). Effective June 17, 2026, the board of directors (the "Board") of the Company appointed John Fraser, the Company's current Chairman of the Board, to serve as its Interim Chief Executive Officer while a search of internal and external candidates is conducted. Mr. Fraser will also serve as the Company's Principal Executive Officer.

​

Mr. Buhle's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Company and Mr. Buhle are discussing a separation agreement in connection with his departure, but the terms have not been finalized as of the date of this Current Report on Form 8-K. The Company will amend this Current Report on Form 8-K to disclose any additional information required by Item 5.02, including the material terms of any separation agreement, within four business days after such information is determined or becomes available.

​

Mr. Fraser, age 66, is the co-founder and co-portfolio manager of Seamark Capital, a fundamentals-based proprietary research growth equities asset management advisor. Mr. Fraser holds a B.S. in Business Administration with emphasis in Economics from Bowling Green State University, and an MBA with emphasis in Finance from The Ohio State University.

​

There are no arrangements or understandings between Mr. Fraser and any other persons pursuant to which he was appointed to his positions with the Company. There are no family relationships between Mr. Fraser and any director or executive officer of the Company.

​

​

​

​